

UROGEN PHARMD MEDICAL AFFAIRS FELLOWSHIP 2024-2025



UroGen[®]
Pharma



Industry Pharmacists
Organization

Table of Contents

1. Message from the President and CEO

2. About UroGen

3. UroGen PharmD Medical Affairs Fellowship

4. Experiences

5. Benefits of the IPhO Partnership

6. Meet The Team

a. Michael Louie, *Senior Vice President*

b. Victoria Tsurutis, *Director of Medical Affairs & Operations*

7. Eligibility/Application Process



Message from President and CEO



Liz Barrett

President and Chief Executive Officer

Thank you for your interest in our Medical Affairs Fellowship Program. At UroGen, we're passionate about making a difference for patients with urothelial and specialty cancers—and we know true progress can only be made when diverse minds come together for this common goal.


Our industry is at a pivotal point where the potential to deliver life-saving and life-altering treatments is immense. For those of us in the field, the chance to contribute to such meaningful work is both a privilege and a responsibility. My personal commitment to this cause stems from a simple truth: the pace of innovation has not kept up with the needs of patients suffering from urologic conditions. It's a reality that motivates us to push harder and think more creatively every day.

The UroGen Pharma Medical Affairs Fellowship Program is an important initiative designed to foster the next generation of Medical Affairs professionals. This program reflects our commitment to scientific innovation, diverse collaboration, and organizational agility to keep pace with the evolving healthcare environment.

We are looking for individuals who are eager to learn, ready to make a difference, and committed to advancing the field of urologic oncology.

About UroGen

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. **UroGen** has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. The company has an FDA approved therapy along with an innovative and



broad pipeline of investigational agents that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on urologic oncology. UroGen is headquartered in Princeton, New Jersey with operations in Israel.

Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

RTGel® and UroGen® are registered trademarks of UroGen Pharma Ltd.



About UroGen's Medical Affairs Fellowship

This is a one-year program focused on opportunities to learn, experience and lead various activities involved within the dynamic functions within a Medical Affairs organization. The UroGen Medical Affairs fellowship is unique as it allows for didactic and experiential cross functional learning opportunities in the form of 1:1 mentorship. This flexibility of the program allows for Fellows to gain broad experiences that will develop them into a well-rounded Medical Affairs professional.

Overall fellow(s) are an essential part of our Medical Affairs team, whose members are positioned throughout the organization to provide evidence-based solutions to patient care challenges within urologic oncology.



Experiences

Fellows will have the opportunity to:



- Gain exposure to key competencies and set up a successful career in Medical Affairs.
- Make an impact in the area of urologic oncology as well as for the patients living with this illness every day.
- Engage in extensive, cross-functional collaboration with headquarters and field-based colleagues.
- Network with a multi-disciplinary team of professionals who share diverse backgrounds and experience within the pharmaceutical and biotechnology industries.
- Build product and therapeutic expertise and provide scientific and clinical support for marketed products and products in development, and appropriately communicate to internal stakeholders and external customers.
- Experience the implementation and tactical execution of medical strategy as well as the gathering of clinical insights through field rides with Medical Science Liaisons. These skills and knowledge enable the Fellow to make significant contributions to the development, launch, and lifecycle management of our product(s).
- Learn and implement the fundamentals of legal and compliance, including key regulatory principles, for drug development and marketed FDA approved products in the pharmaceutical industry.
- Attend medical and scientific meetings to ensure an in-depth understanding of the latest advances and updated medical information that will help shape our Publication and Investigator Sponsored Study strategies.

Benefits of the IPhO Partnership



TEAM

- The Fellow will be a member of the IPhO National Fellows Council (NFC), a diverse group of post-PharmD industry fellows representing programs nationally.



NETWORK

- The Fellow will have opportunities to network and engage with IPhO leadership, other industry pharmacists, and co-fellows across national programs.

- The NFC offers leadership roles for its committees, including Fellows Development, Professional Programming, and Student Development.



LEADERSHIP

- The Fellow will engage in professional development activities including the option to work on diverse projects, such as professional publications and scholarly activities with an IPhO leader and co-fellows from other programs, teach through industry-focused webinars for students, speaking opportunities, etc.



DEVELOPMENT



Meet the Medical Affairs Team



Michael Louie, MD

*Senior Vice President, Medical Affairs
& Clinical Development*

Mike joined UroGen about 1 year ago and brings extensive leadership experience in clinical development, medical affairs, pharmacovigilance, and health economics and outcomes research (HEOR) to our organization.

Mike is a seasoned pharmaceutical executive with a strong background in medical affairs, clinical research, and a focus on addressing unmet medical needs. At UroGen Mike oversees the Medical Affairs and Clinical Development departments and is a valued member of the executive leadership team. He joined UroGen from Esperion Therapeutics, where he led the Medical Affairs team through two product launches, and later led the clinical development team to successfully complete a global 14,000 patient outcomes trial with subsequent regulatory filings in the US and EU. Prior to Esperion, Mike held leadership positions in medical affairs at Regeneron and Pfizer.

Mike received his medical degree from Mount Sinai School of Medicine, completed his residency in internal medicine at Cornell Medical Center, and was a Clinician Scholar at Rockefeller University.

Mike is a lifelong tennis player and enjoys CrossFit. He's a self-proclaimed "foodie" and amateur chef always looking for tips to improve his cooking.

Meet the Medical Affairs Team



Victoria Tsurutis, PharmD, BCPS

Director of Medical Affairs & Operations

Victoria has been with UroGen for 2 years. Her role at UroGen Pharma began as a Medical Science Liaison in the Southeast and Gulf Coast territories. Her role has been expanded to Director of Medical Affairs and Operations where she currently serves as the Medical Information lead and has leadership responsibilities on both the Investigator Initiated Studies and Medical Education Committees. She has extensive experience working cross functionally with clinical development colleagues in addition to commercial, market access, and marketing colleagues.

Prior to UroGen Victoria worked in clinical practice for over 10 years at MUSC, a tertiary care academic teaching facility in Charleston, South Carolina. While practicing as a clinical pharmacist, she predominantly worked with oncology, malignant hematology, and bone marrow transplant patient populations. Additionally, she was a preceptor for students and residents enrolled in both the MUSC College of Pharmacy and Pharmacy Residency Program and was also involved in many multidisciplinary projects during her tenure. She transitioned to industry in 2022 with the goal of making a broader impact on patients with rare cancers.

Victoria is a board certified PharmD. She attended the University of South Carolina for her undergraduate degree (Go Gamecocks!) and completed a Doctorate of Pharmacy degree at the Medical University of South Carolina (MUSC). She is currently board certified in Pharmacotherapy and Medical Affairs.

She loves domestic and international travel and experiencing different cultures and cuisine. She also enjoys home renovations, cooking, and fitness.

Eligibility & Application Process

Potential applicants for the UroGen Medical Affairs fellowship program must meet the following criteria: Graduate from an Accreditation Council for Pharmacy Education (ACPE) accredited Doctor of Pharmacy program by the start of the fellowship, Showcase a genuine interest in the pharmaceutical industry and Medical Affairs, possess excellent collaboration and oral/written communication skills, including presentation skills, be eligible to work in the United States (no visa sponsorship available)

IPhO's Fellow Match is the initial application portal and the following are required:

- Curriculum Vitae (CV)
- Letter of intent
- 1 letter of recommendation
- 3 references
- College transcript (does not have to include spring semester grades)
- Interviews will be conducted on a rolling basis

Contact us at: fellowship@urogen.com

